Lin Hong

Dr. Lin Hong


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2023 in Medicina
Verified
Journal Article
Open access
PDF file
QJQin-Qin Jin
Qin-Qin Jin
JMJie Mei
Jie Mei
LHLin Hong
Lin Hong
RWRui Wang
Rui Wang
SWShuang-Yue Wu
Shuang-Yue Wu
SZShuguang Zhou
Shuguang Zhou
Background and Objectives: Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) are malignant disorders with adverse prognoses for advanced patients. Anoikis, which is involved in tumor metastasis, facilitates the survival and separation of tumor cells from their initial site. Unfortunately, it is rarely studied, and in the literature, studies have only addressed the prognosis character of anoikis for patients with CESC. Materials and Methods: We utilized anoikis-related genes (ANRGs) to construct a prognostic signature in CESC patients that were selected from the Genecards and Harmonizome portals. Furthermore, we revealed the underlying clinical value of this signature for clinical maneuvers by providing clinical specialists with an innovative nomogram on the basis of ANRGs. Finally, we investigated the immune microenvironment and drug sensitivity in different risk groups. Results: We screened six genes from fifty-eight anoikis-related differentially expressed genes in the TCGA-CESC cohort, and we constructed a prognostic signature. Then, we built a nomogram combined with CESC clinicopathological traits and risk scores, which demonstrated that this model may improve the prognosis of CESC patients in clinical therapy. Next, the prognostic risk scores were confirmed to be an independent prognostic indicator. Additionally, we programmed a series of analyses, which included immune infiltration analysis, therapy-related analysis, and GSVA enrichment analysis, to identify the functions and mechanisms of the prognostic models during the progression of cancer in CESC patients. Finally, we performed quantitative reverse transcription polymerase chain reaction (qRT-PCR) to verify the six ANRGs. Conclusions: The present discovery verified that the predictive 6-anoikis-related gene (6-ANRG) signature and nomogram serve as imperative factors that might notably impact a CESC patient’s prognosis, and they may be able to provide new clinical evidence to assume the role of underlying biological biomarkers and thus become indispensable indicators for prospective diagnoses and advancing therapy.

1 June 2025 in Translational Andrology and Urology
Verified
Journal Article
Open access
PDF file
JSJuan Shen
Juan Shen
XLXiang Liu
Xiang Liu
CLChao Li
Chao Li
LHLin Hong
Lin Hong
SZShuguang Zhou
Shuguang Zhou
Background: Bladder cancer (BLCA) is an aggressive malignancy characterized by high rate of recurrence. Its steadily increasing incidence and prevalence have made it one of the most prevalent urogenital tract tumors worldwide. Although immunotherapy serves as a first-line treatment for BLCA, patient prognosis shows significant heterogeneity. Risk stratification through immunotherapy risk scoring could substantially improve prognostic predictions. However, current studies examining the use of immune treatment risk scores to predict the prognosis of immunotherapy across various patients with BLCA remain in its early stages. This research aims to identify immune-related genes as potential biomarkers for BLCA immunotherapy guidelines. Methods: To fill this gap, we used two independent immunotherapy datasets from the “IMvigor210CoreBiologies” package as the training cohort and the Gene Expression Omnibus (GEO) database as the validation cohort to create a risk score signature based on deep learning algorithm to assess the effectiveness and outlook of BLCA immunotherapy. Results: A risk score model comprising three immunotherapeutic-related genes was established and validated, demonstrating significant predictive power and serving as an independent factor for forecasting overall survival (OS) in BLCA immunotherapy. Furthermore, our model revealed a strong association with drug sensitivity responses and identified immune landscape differences among various BLCA patients. Conclusions: We anticipated that the risk score, which is an independent prognostic factor, would be taken into consideration when deciding whether to provide clinical immunotherapy for BLCA patients.